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Prognosis of cerebral cavernomas: on to treatment decisions
In patients with non-traumatic intracerebral haemor-
rhage (ICH) establishment of whether the cause is a 
macrovascular lesion is important, because this might be 
treatable. In a study of 298 patients with ICH who were 
younger than 70 years,1 a standardised diagnostic work-
up of CT angiography within 48 h of onset, followed 
by MRI, magnetic resonance angiography, or digital 
subtraction angiography within 4–8 weeks identiﬁ ed 
69 macrovascular lesions, ten of which were cerebral 
cavernous malformations (CCMs). The advent of MRI has 
enabled easy detection of CCMs, and nowadays a quarter 
of detected vascular malformations are CCMs.2 However, 
whether risks of treatment of CCMs are counterbalanced 
by elimination of the risk of new or recurrent ICH depends 
on the risk of ICH and its clinical consequences. In a meta-
analysis of individual patient data in The Lancet Neurology, 
Margaret Horne and colleagues3 calculated the risks of 
symptomatic ICH for patients with an untreated CCM.
In their comprehensive literature search, the 
investigators identiﬁ ed 22 publications that included 
2957 patients. Data from 1337 patients (45%) could 
not be obtained, showing the challenges of undertaking 
individual patient data analyses. Therefore, the analysis 
was based on data from 1620 patients. During a median 
follow-up of 3·5 years, 204 patients had a symptomatic 
ICH, yielding a 5-year risk of 15·8% (95% CI 13·7–17·9). 
Location of CCM (brainstem vs other) and mode of 
presentation (ICH or focal neurological deﬁ cit [FND] 
vs other) were independently associated with ICH risk 
during follow-up (table). In 640 (40%) of 1620 patients, 
data were also available on the combined outcome of 
ICH or FND; ﬁ ndings were similar, but were less precise. 
Age, sex, and CCM multiplicity did not add independent 
prognostic information.
We commend the investigators for their ability to 
assemble data from seven cohorts, including two from 
Asia, without any missing data. 1159 (72%) of the 
patients presented clinically (ICH, FND, or seizure); in 
the other 461 (28%) patients the CCM was an incidental 
ﬁ nding. Risk of bias of individual studies was low—one 
of the items checked when the investigators applied 
the PRISMA individual participant data statement.4 The 
size of the dataset with 204 primary outcomes allowed 
robust estimation of the joint prognostic information of 
ﬁ ve preselected characteristics.
Horne and colleagues3 chose the ﬁ ve potential 
predictors well on the basis of previous publications 
and practicability, which is in accordance with 
recommendations for modern prognostic research.5 
This careful selection of predictors enhances applicability 
in clinical practice, in part because sophisticated 
laboratory tests are therefore not obligatory to allow 
prediction of risk. External validation of the model was 
not possible because all worldwide available data were 
already used for derivation—a common problem with 
prognostic modelling for rare diseases.
The absolute risks of symptomatic ICH or focal deﬁ cits 
can now be compared with the risks of death, non-fatal 
ICH, or new or worse persistent FND after treatment 
of CCMs. These risks have been reviewed, and seem 
favourable compared with risks of new or recurrent 
ICH.6 The next challenge is to build a decision analytical 
model that compares risks of death, ICH, and FND with 
and without treatment to guide clinicians treating a 
patient with a CCM. Such a model would start with a risk 
prediction model similar to that developed for patients 
with unruptured intracranial aneurysms.7 That analysis 
identiﬁ ed uncertainties that needed further study and 
triggered the development of the PHASES score,8 which 
was also based on a meta-analysis of individual patient 
data. A next step could be to combine the risk prediction 
of ICH with a new meta-analysis of individual patient 
data and prediction model to assess risks of treatment 
according to type of treatment, size and site of the 
CCM, and method of presentation of the patient. The 
decision model should also take into account the time 
dependency of the risks of ICH and FND if the CCM is left 
untreated, since Horne and colleagues3 found a 3·5-times 
Brainstem location Other location All locations
ICH (1620 patients at risk)
ICH or FND presentation 30·8% 18·4% 26·4%
Other presentation 8·0% 3·8% 4·3%
All presentations 27·7% 8·2% 15·8%
ICH or FND (640 patients at risk)
ICH or FND presentation 51% 22% 35%
Other presentation 23% 4% 5%
All presentations 45% 9% 17%
FND=focal neurological deﬁ cit. ICH=intracerebral haemorrhage.
Table: Kaplan-Meier estimates of 5-year risks
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decreased risk of ICH from the ﬁ rst to the ﬁ fth year of 
follow-up in patients presenting with ICH or FND. Finally, 
for the decision to treat, the utility of awareness of an 
untreated incidental CCM should be assessed as another 
element. A modelling approach for patients with CCMs 
is important because randomised trials are not likely to 
be feasible in view of the low prevalence of CCM and the 
potentially strong a-priori beliefs on treatments, which 
might hinder the enrolment of suﬃ  ciently large numbers 
of patients, even in an international collaboration. This 
issue, allegedly, was one of the problems with the ARUBA 
trial,9,10 which assessed medical management with or 
without interventional treatment for unruptured brain 
arteriovenous malformations—a disorder with some 
similarities with CCMs. Hence, meta-analysis of individual 
patient data from properly designed cohort studies of 
the risks of neurosurgery and stereotactic radiosurgery 
are warranted to provide elements for an appropriate 
decision model.
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Human genetics shines a light on ischaemic stroke 
Application of unbiased genome-wide approaches has 
contributed to the understanding of complex disease. 
For example, genome-wide association (GWA) studies 
have been used to identify more than 50 discrete loci 
associated with coronary artery disease.1 Biological 
investigation of the causal genes at these loci has 
provided new insights into the pathogenesis of 
coronary artery disease, as in the case of ADAMTS7.2 
Although ischaemic stroke shares some common 
causes with coronary artery disease, eﬀ orts to dissect 
the genetics of stroke have been arduous because of 
the heterogeneous causes and clinical presentations. 
Ischaemic stroke can be classiﬁ ed into clinically 
distinctive subtypes based on pathophysiological 
diﬀ erences; precise phenotyping of these subtypes 
in patients is crucial to investigate the underlying 
genetic causes. An Article3 in The Lancet Neurology 
by the National Institute of Neurological Disorders 
Stroke Genetics Network presents the largest and 
most comprehensive GWA study of stroke and its 
subtypes so far. The results of this study lend support 
to previous genetic associations with ischaemic 
stroke and identify a new locus on chromosome 1p13. 
Equally important, the study pinpoints the speciﬁ c 
stroke subtypes relevant for the reported genetic 
associations.
Of the replicated loci, it is notable that this report 
conﬁ rms the association between the HDAC9 locus 
and ischaemic stroke, speciﬁ cally in large artery 
atherosclerosis. This same locus—and indeed speciﬁ c 
variant—is also reproducibly associated with coronary 
artery disease, suggesting a shared underlying causal 
gene and mechanism. However, as with all GWA study 
loci, it is now essential to identify the causal gene and 
the mechanisms related to risk of both stroke and 
coronary artery disease associated with this gene; the 
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